This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Cerebrolysin (60 mg Vial)
Cerebrolysin is a porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids that crosses the blood–brain barrier to support neuronal survival[1]. It mimics endogenous neurotrophic factors (e.g., NGF, BDNF) and modulates neuroinflammatory mediators[1][2].
Quick Reference
What is Cerebrolysin?
Research overview based on the cited scientific literature.
• Goal: Support neuroprotection and neuronal survival through neurotrophic factor mimicry[1][2].
• Storage: Lyophilized at room temperature (≤25 °C); reconstituted refrigerated (2–8 °C); do not freeze.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at controlled room temperature ≤25 °C (≤77 °F) in dry, dark conditions; do not freeze[8].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days; protect from light[8].
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Cerebrolysin studied?
Cerebrolysin is a multicomponent peptide preparation derived from porcine brain tissue, containing biologically active neuropeptides and amino acids with molecular weights below 10 kDa[1]. This low molecular weight allows it to cross the blood–brain barrier and exert neurotrophic effects similar to endogenous factors like nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF)[1][2]. Preclinical studies demonstrate neuroprotective effects including reduced infarct size and improved recovery in ischemia models[4][5]. Human trials have examined its use in stroke, dementia, and traumatic brain injury with mixed but generally favorable tolerability profiles[2][3].
What does the research report about Cerebrolysin?
Observations from preclinical and clinical literature.
• Preclinical models consistently show neuroprotective effects including reduced neuronal damage and improved functional recovery after ischemic insult[4][5].
• Meta-analyses of human dementia trials suggest modest cognitive benefits with daily IV infusions[2]; stroke trial results have been more variable[3].
• Generally well tolerated in short-term use[2]; occasional mild injection-site reactions (redness, discomfort) may occur with subcutaneous administration.
• Rare reports of dizziness, headache, or gastrointestinal upset; discontinue and consult a professional if significant adverse effects occur.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Cerebrolysin?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
